» Articles » PMID: 28367145

Safety Evaluation of a Novel Strain of

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2017 Apr 4
PMID 28367145
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Commensal non-toxigenic confers powerful health benefits to the host, and has recently been identified as a promising probiotic candidate. We previously isolated strain ZY-312 and identified it as a novel strain based on 16S rRNA sequencing and morphological analyses. We also determined that ZY-312 displayed desirable probiotic properties, including tolerance to simulated digestive fluid, adherence, and safety. In this study, we aim to investigate whether ZY-312 meets the safety criteria required for probiotic bacteria through comprehensive and systematic evaluation. Consequently, the fatty acid profile, metabolite production, and biochemical activity of strain ZY-312 were found to closely resemble descriptions of in Bergey's manual. Taxonomic identification of strain ZY-312 based on whole genome sequencing indicated that ZY-312 and ATCC 25285 showed 99.99% similarity. The 33 putative virulence-associated factors identified in ZY-312 mainly encoded structural proteins and proteins with physiological activity, while the lack of indicated that ZY-312 was non-toxigenic. safety was proven in both normal and immune-deficient mice. The 11 identified antibiotic resistance genes were located on the chromosome rather than on a plasmid, ruling out the risk of plasmid-mediated transfer of antibiotic resistance. , ZY-312 showed resistance to cefepime, kanamycin, and streptomycin. Finally, and notably, ZY-312 exhibited high genetic stability after 100 passages . This study supplements the foundation work on the safety evaluation of ZY-312, and contributes to the development of the first probiotic representative from the dominant Bacteroidetes phylum.

Citing Articles

capsular polysaccharide A ameliorates ulcerative colitis in rat by recovering intestinal barrier integrity and restoring gut microbiota.

Zhong Y, Chang X, Zhao Z, Zheng L, Kuang G, Li P Front Pharmacol. 2025; 15():1402465.

PMID: 39776580 PMC: 11703662. DOI: 10.3389/fphar.2024.1402465.


Unraveling Whole-Genome Sequence and Functional Characterization of PH3.

Zhang X, Liang J, Zhang D, Wang L, Ye S Foods. 2024; 13(22).

PMID: 39593971 PMC: 11593290. DOI: 10.3390/foods13223555.


Research trends of next generation probiotics.

Hasnain M, Kang D, Moon G Food Sci Biotechnol. 2024; 33(9):2111-2121.

PMID: 39130671 PMC: 11315851. DOI: 10.1007/s10068-024-01626-9.


Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies.

Koning M, Herrema H, Nieuwdorp M, Meijnikman A Gut Microbes. 2023; 15(1):2226922.

PMID: 37610978 PMC: 10305510. DOI: 10.1080/19490976.2023.2226922.


AFB Microbial Degradation by WJ6 and Its Degradation Mechanism Exploration Based on the Comparative Transcriptomics Approach.

Yang P, Wu W, Zhang D, Cao L, Cheng J Metabolites. 2023; 13(7).

PMID: 37512492 PMC: 10385142. DOI: 10.3390/metabo13070785.


References
1.
Luo R, Liu B, Xie Y, Li Z, Huang W, Yuan J . SOAPdenovo2: an empirically improved memory-efficient short-read de novo assembler. Gigascience. 2013; 1(1):18. PMC: 3626529. DOI: 10.1186/2047-217X-1-18. View

2.
Round J, Mazmanian S . Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A. 2010; 107(27):12204-9. PMC: 2901479. DOI: 10.1073/pnas.0909122107. View

3.
Sanders M, Akkermans L, Haller D, Hammerman C, Heimbach J, Hormannsperger G . Safety assessment of probiotics for human use. Gut Microbes. 2011; 1(3):164-85. PMC: 3023597. DOI: 10.4161/gmic.1.3.12127. View

4.
Mazmanian S, Kasper D . The love-hate relationship between bacterial polysaccharides and the host immune system. Nat Rev Immunol. 2006; 6(11):849-58. DOI: 10.1038/nri1956. View

5.
McKenney P, Pamer E . From Hype to Hope: The Gut Microbiota in Enteric Infectious Disease. Cell. 2015; 163(6):1326-32. PMC: 4672394. DOI: 10.1016/j.cell.2015.11.032. View